Australia's TGA Issues Infringement Notice for Nicotine E-Cigarette Promotion

Aug.03.2022
The TGA has issued a $2664 infringement notice to an individual in NSW for promoting and selling nicotine e-cigarettes without proper registration.

The Australian Therapeutic Goods Administration (TGA) has issued a $2664 infringement notice to an individual in New South Wales for allegedly promoting and selling nicotine e-cigarette products on their website.


Despite being informed of the relevant laws, this individual continued to promote nicotine e-cigarette products to the public. In Australia, these products are considered prescription drugs and can only be obtained through a valid prescription from a registered Australian doctor. Advertising to the public is only allowed under the conditions of the 2021 Therapeutic Goods (Restriction and Prohibition of Nicotine) Advertising Code (No. 2).


The law focuses on the importation, manufacture, advertisement, and supply of nicotine e-cigarette products. It aims to balance the need to prevent youth and young adults from using nicotine e-cigarettes (and potentially developing a smoking habit) while providing support for current smokers to access appropriate medical means to quit smoking.


This article's content is compiled from third-party information and is intended solely for industry exchange and learning.


This article does not represent the viewpoint of 2FIRSTS, and 2FIRSTS cannot confirm the truth or accuracy of the content. The compilation of this article is only intended for industry communication and research purposes.


Due to limitations in the translator's skill level, the translated article may not fully express the same meaning as the original. Please refer to the original article for accuracy.


2FIRSTS is completely aligned with the Chinese government's views and positions on any domestic, Hong Kong, Macau, Taiwan, and international issues.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Khmelnytskyi, Ukraine: counterfeit nicotine mixes and e-cigarette e-liquids seized, valued at over US$276,000
Khmelnytskyi, Ukraine: counterfeit nicotine mixes and e-cigarette e-liquids seized, valued at over US$276,000
According to UNN, law enforcement in Ukraine’s Khmelnytskyi region disrupted a group accused of selling illegally produced nicotine-containing mixtures and e-cigarette e-liquids without licenses or permits. The Prosecutor General’s Office said the overall value of the seized items exceeds UAH 12 million (about US$276,000). Motions were filed to arrest the seized property, and decisions are pending on necessary forensic examinations. (FX used: 1 UAH = US$0.023, as provided by the user.)
Jan.14 by 2FIRSTS.ai
BAT rolls out VELO nicotine pouches in Argentina as social media buzzes about ZYN distribution
BAT rolls out VELO nicotine pouches in Argentina as social media buzzes about ZYN distribution
BAT Argentina says it has launched VELO nicotine pouches in Argentina, positioning the product as an adult alternative that contains no tobacco and involves no combustion. At the same time, social media discussion and media reporting indicate that Philip Morris International’s ZYN nicotine pouches are also being distributed through Argentine channels.
Jan.12 by 2FIRSTS.ai
KT&G’s Heated Tobacco Brand “lil” Named to Korea’s Brand Hall of Fame for Eighth Consecutive Year
KT&G’s Heated Tobacco Brand “lil” Named to Korea’s Brand Hall of Fame for Eighth Consecutive Year
KT&G said its heated tobacco brand “lil” was selected as an outstanding brand in the heated tobacco category of the “2026 Korea Brand Hall of Fame,” marking its eighth straight year on the list. The awards are organized by the Industrial Policy Research Institute (IPS) and determined through a composite evaluation of customer satisfaction, brand value and market performance.
Jan.26 by 2FIRSTS.ai
Cambodia: Phnom Penh authorities seize 2,000+ vape devices and arrest two alleged distributors
Cambodia: Phnom Penh authorities seize 2,000+ vape devices and arrest two alleged distributors
Kiripost reports that authorities seized more than 2,000 electronic smoking devices and arrested two alleged distributors in Phnom Penh’s Toul Kork district, prompting health advocates to warn that inconsistent enforcement is undermining Cambodia’s crackdown on illegal e-cigarettes and shisha.
Jan.13 by 2FIRSTS.ai
From Tamarind’s AI Shift to Industry Restructuring, The ‘Amazon Moment’ for Nicotine Is Approaching
From Tamarind’s AI Shift to Industry Restructuring, The ‘Amazon Moment’ for Nicotine Is Approaching
Tamarind Intelligence’s decision to appoint a technology-sector executive as chief executive officer signals more than a leadership reshuffle at a specialist data firm. It reflects a broader structural shift across the global nicotine industry, where companies, regulators and intelligence providers are embedding artificial intelligence into core operations.
Special Report
Feb.18
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11